Galashiels, United Kingdom
Galashiels, United Kingdom
SEARCH FILTERS
Time filter
Source Type

News Article | May 12, 2017
Site: globenewswire.com

Dublin, May 12, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Transdermal Patch Market & Clinical Pipeline Outlook 2022" report to their offering. Global Transdermal Patch Market & Clinical Pipeline Outlook 2022 report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies. Currently there 40 transdermal patches available in the market and more than 70 patches are in clinical pipeline. Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch. Strong clinical pipeline could be observed in case of transdermal patches which reflect the interest of pharmaceutical companies in this segment. Before marketing approval they have to undergo strict testing and checking for various qualitative parameters. They must be stable, chemically unreactive, hypo allergic, nontoxic and easy to manufacture. High throughput methods are expected to increase the suitable polymer screening rates along with reduced time consumption. Bioequivalence of therapeutic in transdermal patch with same drug administrated via different route have known efficacy must be shown. Similarly, independent of patch type they must show bioequivalence in clinical trials before getting marketing approval from medical regulatory authorities. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Global Transdermal Patch Market & Clinical Pipeline Outlook 2022 report highlights: - Introduction & Classification of Transdermal Patch - Mechanism of Transdermal Patch Drug Delivery - Transdermal Patch v/s Traditional Drug Delivery Methods - Global Transdermal Patch Clinical Pipeline Overview - Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase - Global Transdermal Patch Market Future Prospects Key Topics Covered: 1. Introduction to Transdermal Patch 2. Classification of Transdermal Patches 2.1 Single/ Multiple-Layer Drug-in-Adhesive 2.2 Reservoir Transdermal Patches 2.3 Matrix Based Transdermal Patches 2.4 Vapor Patch 2.5 Active and Passive Patch 3. Why There Exist Need for Transdermal Patches? 4. Mechanism of Transdermal Patch Drug Delivery 4.1 Properties of Transdermal Therapeutics 4.2 Components of Transdermal Patch 4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch 5. Transdermal Patch v/s Traditional Drug Delivery Methods 6. Global Transdermal Patch Market Outlook 6.1 Global Market Scenario 6.2 Regional Trends 7. Global Transdermal Patch Clinical Pipeline Overview 7.1 By Phase 7.2 By Region/Country 7.3 By Drug Class/Molecule 7.4 By Company 7.5 By Orphan & Fast Track Status 7.6 By Mode of Action 8. Global Transdermal Patch Market Dynamics 8.1 Favorable Market Parameters 8.2 Commercialization Challenges 9. Global Transdermal Patch Market Future Prospects 10. Global Transdermal Patch Clinical Insight 10.1 Unknown 10.2 Research 10.3 Preclinical 10.4 Clinical 10.5 Phase-I 10.6 Phase-I/II 10.7 Phase-II 10.8 Phase-II/III 10.9 Phase-III 10.10 Preregistration 10.11 Registered 11. Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase 12. Competitive Landscape 12.1 3M Pharmaceuticals 12.2 Acrux 12.3 Agile Therapeutics 12.4 Allergan 12.5 ANI Pharmaceuticals 12.6 Antares Pharma 12.7 Bayer HealthCare Pharmaceuticals 12.8 Corium International 12.9 Chase Pharmaceuticals 12.10 DURECT Corporation 12.11 Endo Pharmaceuticals 12.12 Fempharm 12.13 Hisamitsu Pharmaceutical 12.14 Immune Pharmaceuticals 12.15 Imprimis Pharmaceuticals 12.16 Ipsen Bioscience 12.17 Johnson & Johnson 12.18 LaSalle Laboratories 12.19 Lavipharm-increase 12.20 MINRAD International 12.21 NeurogesX 12.22 Noven Pharmaceuticals 12.23 NuPathe 12.24 Nuvo Research 12.25 Novartis 12.26 Pain Therapeutics 12.27 ProStrakan 12.28 Purdue Pharma 12.29 Sanofi 12.30 Scilex Pharmaceuticals 12.31 Senju Pharmaceutical 12.32 Somerset Pharmaceuticals 12.33 Teikoku Seiyaku 12.34 Therapeutic Discovery Corporation 12.35 Transdermal Delivery Solutions Corp 12.36 UCB-full form 12.37 Xel Pharmaceuticals 12.38 Zosano Pharma For more information about this report visit http://www.researchandmarkets.com/research/d2p9zx/global


News Article | May 29, 2017
Site: www.prnewswire.com

NEW YORK, May 29, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are further analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Read the full report: http://www.reportlinker.com/p04910451/Global-Testosterone-Replacement-Therapy-TRT-Pharmaceuticals.html Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 29 companies including many key and niche players such as - AbbVie, Inc. - Acerus Pharmaceuticals Corporation - Acrux Limited - Antares Pharma, Inc. Read the full report: http://www.reportlinker.com/p04910451/Global-Testosterone-Replacement-Therapy-TRT-Pharmaceuticals.html I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study Topicals Patches Others II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW TRT Market in a State of Flux List of FDA Approved TRTs by Formulation and Year of Approval Timeline for Launch of Various Types of Testosterone Replacement Therapies Table 1: World Hypogonadism Prevalence by Age Group: Percentage of the Disorder in 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, and >80 Age Groups (includes corresponding Graph/Chart) Recently Approved/ Pipeline Testosterone Replacement Therapy Products US Dominates the Global TRT Market Markets, Other than the US, to Witness Tremendous Growth Topicals Dominate the US Market, Conventional Drugs Rule Elsewhere Leading TRT Products Available in the Market Cardiovascular Risks Taint the TRT Market 2. GROWTH DRIVERS AND MARKET TRENDS Aging Global Population Drives Adoption Table 2: Percentage of Total Population above 65 Years of Age in Select Countries for 2000 and 2025 (F) (includes corresponding Graph/Chart) Table 3: Global Male Population Distribution (15-64 Yrs) by Geographic Region: 2015 (includes corresponding Graph/Chart) Table 4: Global Male Population Distribution (65+Yrs) by Geographic Region: 2015 (includes corresponding Graph/Chart) Undiagnosed Patients - A Strong Indicator of Growth Potential Rising Awareness - A Critical Factor for Growth Untapped Developing Markets - The Future Growth Engine for TRT Emerging Data on Positive Impact on Co-morbidities to Support Growth Debunking Conventional Wisdom, New Studies Dissociate Prostate Cancer Risk with TRT Marketing Campaigns and Patient Referrals to Fuel Growth Easy-to-use Formulations - A Major Boost to TRT Market Testosterone as Treatment for Other Conditions - A Growing Area of Focus 3. COMPETITION TRT- A Highly Consolidated Market Table 5: Sales of Select testosterone Replacement Therapies: 2015 & 2016 (in US$ Million) (includes corresponding Graph/Chart) Entry of Large Multinational Players Generic Incursion - A Major Threat Expiration of Patents and Market Exclusivity of Leading TRT Brands in the US An Overview of Select Drugs on The Market AndroGel (AbbVie) AndroGel's Market Performance Raises Concerns for AbbVie Axiron (Eli Lilly) Axiron - A Comparison with Other Products Axiron's Patent Profile Testim (Endo/Auxilium) Testim Scores High on Efficacy over AndroGel Small Packaging Works for Testim Testim' Sales Continue to Plunge Androderm (Actavis) Fortesta (Endo Pharmaceuticals) Tostran (Kyowa Kirin) Natesto™ TRT - A Comparative Review Inherent Attributes to Help Natesto Scale Sizable Growth Threat from New Products Pipeline Analysis Oral Drugs Dominate Drug Development Pipeline Lipocine's Tlando Hits Regulatory Bump Uncertainly Looms Large Over Enclomiphene's Pending Approval Clarus Persists with its Oral TRT VIBEX QS T - A New Hope to Injectables Users Rextoro (formerly CLR-610) New Drug in Development Promises Availability of Native Oral Testosterone Spray-on Testosterone - A New Chapter in Topical Testosterone Therapies 4. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW Testosterone - An Introduction Testosterone Deficiency Primary Hypogonadism Secondary Hypogonadism Symptoms General Symptoms Clinical Symptoms Table 6: Major Symptoms in Hypogonadal Patients: Percentage of Hypogonadal Patients Affected with Moderate to Severe Symptoms of Low Energy Levels, Irritability, Sparse Beard, Diminished Libido, and Sleepiness After Lunch (includes corresponding Graph/Chart) Causes Co-Morbid Conditions Table 7: Hypogonadism Prevalence in Some Common Medical Conditions (includes corresponding Graph/Chart) Diabetes and Hypogonadism Diagnosis Testosterone Replacement Testosterone Replacement Therapy - Evolution Topicals Patches Others Injections Orals Pellets A Comparison of Key Benefits and Drawbacks of Existing Testosterone Preparations Major Potential Benefits of TRT Major Potential Risks of TRT Precautions Treatment Alternatives 5. PRODUCT LAUNCHES/APPROVALS Perrigo Obtains FDA Clearance of ANDA for Generic Axiron Acerus Launches Natesto™ in Canada Endo Pharmaceuticals Launches Natesto™ Perrigo Releases AB Therapeutics Equivalent of Testosterone Gel Endo Introduces Authorized Generic FORTESTA® Gel Auxilium Rolls Out Authorized Generic Version of Testim Endo Gets FDA Nod for Aveed FDA Denies Rextoro Oral Testosterone by Clarus Therapeutics FDA Approves sNDA for STENDRA Endo International Launches Generic Version of its Fortesta MonoSol Rx Launches Clinical Trial of MSRX-110 Perrigo Receives AB Therapeutic Equivalent Rating from FDA for Testosterone Gel FDA Confirms Endpoints for ZA-304 and ZA-305 Studies Auxilium and Prasco Launch Testim® Generic FDA Approves NDA for Vogelxo USFDA Approves Natesto Testosterone Nasal Gel BioThermo Labs Introduces T9 Testosterone Supplement iSatori Launches Fenu Test HRTI Obtains FDA Clearance for Commencing Testagen® TDS Clinical Trials Eli Lily Launches Axiron® in Canada FDA Approves Generic Depo-Testosterone Injection of Sun Pharmaceutical Perrigo Obtains FDA Approval for AndroGel® 1% TestoMeds Launches Androfeme, Andromforte and Profeme Testosterone Replacement Creams 6. RECENT INDUSTRY ACTIVITY Lipocine Finishes Enrollment for New Dosage Studies on LPCN 1021 FDA Accepts NDA for Antares Pharma's QST Teva Sells Actavis' Operations in UK and Ireland to Accord TesoRx and ASKA Team Up to Commercializes Oral TRT in Japan Acerus Grants Korean Commercialization License for NATESTO to Hyundai Pharm Repros Files for European Approval of Enclomiphene Teva Acquires Actavis Generics Acerus Consummates Transition of NATESTO from Endo to Aytu FDA Rejects NDA for Lipocine's Oral Testosterone Product ProStrakan Changes Name to Kyowa Kirin Apricus Biosciences Shelves Fispemifene Developmental Trials Acerus Cancels Commercialization Deal for NATESTO with Endo Ventures Novartis and Phase 4 Partners form Mereo BioPharma Group Repros Gets Complete Response Letter of NDA Rejecting Approval for Enclomiphene ANI Acquires Approved NDA for Teva's Testosterone Gel 1% Endo Takes Over Auxilium Pharmaceuticals Trimel Files for Approval for Natesto with Health Canada Trimel Confers Endo with Natesto Marketing Rights TesoRx Awards Aspen Global with Select International License of TSX-002 Viramal Acquires TestoCream License from Aptys Vivus Provides Auxilium North American Marketing Rights for STENDRA CoreRx and TesoRx Pharma Form Production Joint Venture for TSX-002 Eli Lilly Files Lawsuit against Perrigo for Infringing Axiron Patents Perrigo Files for Generic Axiron Approval with FDA Auxilium Wins Patent Challenges for Testim Auxilium Pharmaceuticals Takes Over Actient Holdings Ferring Submits Patent Application for New Testosterone Formulations in Australia Perrigo Submits ANDA for Testosterone 1.62% with the US FDA Watson Pharmaceuticals Rebrands to Actavis US FDA Accepts to Review Complete Response Submission for NDA of Endo Pharmaceuticals's Aveed Lipocine Announces Positive Phase I Clinical Trial for LPCN 1111 Candidate 7. FOCUS ON SELECT PLAYERS AbbVie, Inc. (US) Acerus Pharmaceuticals Corporation (Canada) Acrux Limited (Australia) Antares Pharma, Inc. (US) Bayer HealthCare Pharmaceuticals (Germany) Eli Lilly and Company (US) Endo Pharmaceuticals Inc. (US) Kyowa Kirin (UK) 8. GLOBAL MARKET PERSPECTIVE Table 8: World Recent Past, Current & Future Analysis for Testosterone Replacement Therapy (TRT) by Geographic Region - US, Canada, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 9: World Historic Review for Testosterone Replacement Therapy (TRT) by Geographic Region - US, Canada, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 10: World 14-Year Perspective for Testosterone Replacement Therapy (TRT) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) Table 11: World Recent Past, Current & Future Analysis for Testosterone Replacement Therapy (TRT) by Product Segment - Topicals, Patches and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 12: World Historic Review for Testosterone Replacement Therapy (TRT) by Product Segment - Topicals, Patches and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 13: World 14-Year Perspective for Testosterone Replacement Therapy (TRT) by Product Segment - Percentage Breakdown of Dollar Sales for Topicals, Patches and Others Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) III. MARKET 1. THE UNITED STATES A.Market Analysis Hypogonadism - High Prevalence, Low Treatment, Offers Increasing Potential Topical Gels - The Largest Selling Segment Table 14: Total TRT Prescriptions Trends in the US: Number of Total Prescriptions (March 2015 - December 2016) (includes corresponding Graph/Chart) A Comparison of Commonly Prescribed Topical TRT Products in the US "Low T" Trend Litigations New Products Strive to Address Transference Issues High-Concentration Products Gain Market Share in the Topicals Market Debate Continues Over the Need for TRT Big Pharma Spends Millions to Push TRT Sales Increasing Ad Spending Draws Flak Product Landscape AndroGel Retains Leadership in Total Prescriptions Table 15: Leading Drugs in the US TRT Market (2015): Percentage Breakdown of Value Sales for Androderm, Androgel, Axiron, Fortesta, Testim, Transdermal Testosterone and Others (includes corresponding Graph/Chart) Table 16: TRT Prescriptions in the US (2015): Percentage Breakdown of Total Prescriptions for Androgel, Axiron, Fortesta, Transdermal Testosterone and Injectables (includes corresponding Graph/Chart) AbbVie Fights on for AndroGel's Market Sustenance Axiron Faces Tough Market Conditions Table 17: Axiron Quarterly Sales Worldwide: FY2012 through FY2016 (includes corresponding Graph/Chart) Co-Pay Scheme Helps Axiron Attract Users Testim Revenues Head South Impending Patent Expiries Patent Expiries of Leading TRT Brands in the US Generics Hurt Sales of Branded Drugs FDA Mandates Labeling Changes despite Lack of Consensus Related to Cardiac Events after TRT Product Launches/Approvals Strategic Corporate Developments Key Players B.Market Analytics Table 18: US Recent Past, Current & Future Analysis for Testosterone Replacement Therapy by Product Segment - Topicals, Patches and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 19: US Historic Review for Testosterone Replacement Therapy by Product Segment - Topicals, Patches and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 20: US 14-Year Perspective for Testosterone Replacement Therapy by Product Segment - Percentage Breakdown of Dollar Sales for Topicals, Patches and Others Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) 2. CANADA A.Market Analysis Current & Future Analysis Available TRT Therapies in Canada Product Approvals/Launches Strategic Corporate Developments Acerus Pharmaceuticals Corporation - A Major Canada-based TRT Player B.Market Analytics Table 21: Canadian Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 22: Canadian Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 3. EUROPE A.Market Analysis Current & Future Analysis Gels to Drive European TRT Market Lower Normal Serum Testosterone Concentration in Select European Nations Strategic Corporate Developments B.Market Analytics Table 23: European Recent Past, Current & Future Analysis for Testosterone Replacement Therapy by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 24: European Historic Review for Testosterone Replacement Therapy by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 25: European 14-Year Perspective for Testosterone Replacement Therapy by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart) 3a. FRANCE Market Analysis Table 26: French Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 27: French Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 3b. GERMANY A.Market Analysis Current & Future Analysis Strategic Corporate Development Bayer Healthcare Pharmaceuticals - A Key Player in the TRT Market B.Market Analytics Table 28: German Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 29: German Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 3c. ITALY Market Analysis Table 30: Italian Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 31: Italian Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 3d. THE UNITED KINGDOM A.Market Analysis Market Overview Product Launch/Approval Strategic Corporate Development Select Key Player B.Market Analytics Table 32: UK Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 33: UK Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 3e. SPAIN Market Analysis Table 34: Spanish Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 35: Spanish Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 3f. REST OF EUROPE A.Market Analysis Current & Future Analysis Product Launch B.Market Analytics Table 36: Rest of Europe Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 37: Rest of Europe Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 4. ASIA-PACIFIC A.Market Analysis Current & Future Analysis Increasing Use of Testosterone in Australia Strategic Corporate Developments Select Key Player B.Market Analytics Table 38: Asia-Pacific Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 39: Asia-Pacific Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 5. LATIN AMERICA Market Analysis Table 40: Latin American Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 41: Latin American Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 6. REST OF WORLD A.Market Analysis Current & Future Analysis Product Launch B.Market Analytics Table 42: Rest of World Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 43: Rest of World Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 29 (including Divisions/Subsidiaries - 31) The United States (17) Canada (2) Japan (2) Europe (7) - Germany (1) - The United Kingdom (4) - Rest of Europe (2) Asia-Pacific (Excluding Japan) (3) Read the full report: http://www.reportlinker.com/p04910451/Global-Testosterone-Replacement-Therapy-TRT-Pharmaceuticals.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-testosterone-replacement-therapy-trt---pharmaceuticals-300465051.html


News Article | May 12, 2017
Site: globenewswire.com

Dublin, May 12, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Transdermal Patch Market & Clinical Pipeline Outlook 2022" report to their offering. Global Transdermal Patch Market & Clinical Pipeline Outlook 2022 report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies. Currently there 40 transdermal patches available in the market and more than 70 patches are in clinical pipeline. Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch. Strong clinical pipeline could be observed in case of transdermal patches which reflect the interest of pharmaceutical companies in this segment. Before marketing approval they have to undergo strict testing and checking for various qualitative parameters. They must be stable, chemically unreactive, hypo allergic, nontoxic and easy to manufacture. High throughput methods are expected to increase the suitable polymer screening rates along with reduced time consumption. Bioequivalence of therapeutic in transdermal patch with same drug administrated via different route have known efficacy must be shown. Similarly, independent of patch type they must show bioequivalence in clinical trials before getting marketing approval from medical regulatory authorities. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Global Transdermal Patch Market & Clinical Pipeline Outlook 2022 report highlights: - Introduction & Classification of Transdermal Patch - Mechanism of Transdermal Patch Drug Delivery - Transdermal Patch v/s Traditional Drug Delivery Methods - Global Transdermal Patch Clinical Pipeline Overview - Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase - Global Transdermal Patch Market Future Prospects Key Topics Covered: 1. Introduction to Transdermal Patch 2. Classification of Transdermal Patches 2.1 Single/ Multiple-Layer Drug-in-Adhesive 2.2 Reservoir Transdermal Patches 2.3 Matrix Based Transdermal Patches 2.4 Vapor Patch 2.5 Active and Passive Patch 3. Why There Exist Need for Transdermal Patches? 4. Mechanism of Transdermal Patch Drug Delivery 4.1 Properties of Transdermal Therapeutics 4.2 Components of Transdermal Patch 4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch 5. Transdermal Patch v/s Traditional Drug Delivery Methods 6. Global Transdermal Patch Market Outlook 6.1 Global Market Scenario 6.2 Regional Trends 7. Global Transdermal Patch Clinical Pipeline Overview 7.1 By Phase 7.2 By Region/Country 7.3 By Drug Class/Molecule 7.4 By Company 7.5 By Orphan & Fast Track Status 7.6 By Mode of Action 8. Global Transdermal Patch Market Dynamics 8.1 Favorable Market Parameters 8.2 Commercialization Challenges 9. Global Transdermal Patch Market Future Prospects 10. Global Transdermal Patch Clinical Insight 10.1 Unknown 10.2 Research 10.3 Preclinical 10.4 Clinical 10.5 Phase-I 10.6 Phase-I/II 10.7 Phase-II 10.8 Phase-II/III 10.9 Phase-III 10.10 Preregistration 10.11 Registered 11. Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase 12. Competitive Landscape 12.1 3M Pharmaceuticals 12.2 Acrux 12.3 Agile Therapeutics 12.4 Allergan 12.5 ANI Pharmaceuticals 12.6 Antares Pharma 12.7 Bayer HealthCare Pharmaceuticals 12.8 Corium International 12.9 Chase Pharmaceuticals 12.10 DURECT Corporation 12.11 Endo Pharmaceuticals 12.12 Fempharm 12.13 Hisamitsu Pharmaceutical 12.14 Immune Pharmaceuticals 12.15 Imprimis Pharmaceuticals 12.16 Ipsen Bioscience 12.17 Johnson & Johnson 12.18 LaSalle Laboratories 12.19 Lavipharm-increase 12.20 MINRAD International 12.21 NeurogesX 12.22 Noven Pharmaceuticals 12.23 NuPathe 12.24 Nuvo Research 12.25 Novartis 12.26 Pain Therapeutics 12.27 ProStrakan 12.28 Purdue Pharma 12.29 Sanofi 12.30 Scilex Pharmaceuticals 12.31 Senju Pharmaceutical 12.32 Somerset Pharmaceuticals 12.33 Teikoku Seiyaku 12.34 Therapeutic Discovery Corporation 12.35 Transdermal Delivery Solutions Corp 12.36 UCB-full form 12.37 Xel Pharmaceuticals 12.38 Zosano Pharma For more information about this report visit http://www.researchandmarkets.com/research/d2p9zx/global

Loading ProStrakan collaborators
Loading ProStrakan collaborators